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OBJECTIVE: To analyze cytokine gene expression in keratinocytes from patients with systemic lupus erythematosus
(SLE).
INTRODUCTION: Keratinocytes represent 95% of epidermal cells and can secrete several cytokines.
METHODS: Keratinocytes were obtained by laser microdissection from 21 patients with SLE (10 discoid and 11 acute
lesions) at involved and uninvolved sites. All patients were receiving a low/moderate prednisone dose and 18 were
receiving chloroquine diphosphate. IL-2, IL-5, TNF-a and IFN-c gene expression was evaluated by real-time PCR and
expressed as the ratio (R) to a pool of skin samples from 12 healthy volunteers.
RESULTS: Heterogeneity in cytokine gene expression was found among patients with SLE. Eighteen of 38 valid SLE
samples (47%) presented overexpression (R.1) of at least one cytokine. Lesional skin samples tended to show
higher cytokine expression than samples from uninvolved skin (p= 0.06). IL-5 and IFN-c were the most commonly
overexpressed cytokines. Samples with cytokine overexpression corresponded to more extensive and severe lesions.
Prednisone dose did not differ between samples without cytokine overexpression (15.71¡3.45 mg/day) and those
with overexpressed cytokines (12.68¡5.41 mg/day) (p = 0.216). Samples from all patients not receiving diphosphate
chloroquine had at least one overexpressed cytokine.
CONCLUSIONS: The heterogeneous keratinocyte cytokine gene expression reflects the complex immunological and
inflammatory background in SLE. Patients with severe/extensive skin lesions showed a higher frequency of cytokine
gene overexpression. Increased IFN-c and IL-5 expression suggests that Th1 and Th2 cells are involved in SLE skin
inflammation. The possibility that prednisone and antimalarial drugs may have contributed to low cytokine gene
expression in some samples cannot be ruled out.
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INTRODUCTION
Skin lesions occur in roughly 80% of patients with
systemic lupus erythematosus (SLE), with variable severity
and morbidity.1 The most common forms of skin involve-
ment in SLE are acute exanthema, discoid lupus, photo-
sensitive erythema and subacute cutaneous lupus
erythematosus. The clinical and histopathologic features of
each of these lesions have been extensively defined.1,2
Immunologic disorders in several inflammatory diseases
have been characterized according to the dominant cytokine
pattern of the infiltrating CD4+ T cells. A Th1 pattern is
characterized by predominance of interleukin 2 (IL-2) and
interferon-c (IFN-c), whereas a Th2 pattern is characterized
by predominance of IL-4, IL-5, IL-6, IL-10 and IL-13. The
type and intensity of the immune disorder may vary from
organ to organ in each pathologic condition. Keratinocytes
represent 95% of the cells in the epidermis and have been
shown to be involved in the production of a variety of
cytokines, such as IL-1, tumor necrosis factor-a (TNF-a),
IL-6 and granulocyte macrophage-colony-stimulating factor.
A Th1 pattern has been well documented in skin lesions
from patients with tuberculoid leprosy and psoriasis.3,4
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Conversely, a Th2 pattern has been demonstrated in skin
lesions of lepromatous leprosy and Sezary syndrome.3,5
The cytokine pattern in skin lesions from patients with
SLE has already been discussed in previous studies.
Nu¨rnberg et al. examined protein and messenger RNA
(mRNA) expression for IL-6 in the epidermal layer of
affected and non-affected skin in patients with acute,
subacute and discoid lupus erythematosus.6 Increased
expression of IL-6 and its mRNA was observed in the basal
layer of keratinocytes in most samples of affected skin but
not in non-affected samples.6 Using reverse transcriptase
polymerase chain reaction (RT-PCR), Stein et al. studied
mRNA production for several cytokines in whole skin
samples from healthy volunteers and from acute, subacute
cutaneous and discoid lesions of patients with SLE. IFN-c
and IL-5 were detected in the majority of samples from
patients with SLE, IL-10 was present in half the samples, IL-
2 in a few samples and IL-4 was not detected. Normal
samples expressed mRNA only for IFN-c and IL-10.7 Using
a similar approach, Toro et al. demonstrated elevated levels
of mRNA for IFN-c, IL-2 and TNF-a in whole skin samples
from discoid lupus lesions. No transcripts for IL-1 and IL-4
were detected in these lesions.8
The contribution of epidermal keratinocytes to the
cytokine milieu in the various SLE skin lesions has not
been fully elucidated since most studies used whole skin
as source of mRNA. It is well known that epidermal
keratinocytes are considerably affected by ultraviolet
radiation and that this environmental factor is associated
with triggering or exacerbation of SLE. This study was
designed to analyze the cytokine expression pattern in
isolated epidermal keratinocytes in patients with acute skin
lesions and discoid SLE. Based on previous literature
findings, we selected for study Th2 cytokine IL-5 and Th1
cytokines IL-2 and IFN-c. Owing to the remarkable
response of SLE skin lesions to drugs that interfere with
TNF-a (e.g., thalidomide), we analyzed the expression of
this cytokine also.
MATERIALS AND METHODS
Two skin 4 mm punch biopsy samples (one from affected
and one from non-affected skin) were obtained from each of
21 sequentially selected adults with active SLE (11 with
acute lesions and 10 with discoid lesions)—that is, 22
samples from patients with acute lesions and 20 from
patients with discoid lesion. Skin 4 mm punch biopsy
samples were also obtained from 12 healthy volunteers.
Patients with SLE were classified according to the criteria
established by the American College of Rheumatology.9
Patients using immunosuppressive drugs other than gluco-
corticosteroids were excluded. All subjects signed an
informed consent form previously approved by the institu-
tional ethics committee. Samples were immediately frozen
in liquid nitrogen and stored at 280 C˚ until use. Frozen
samples were subjected to microdissection under optical
microscopy10 and 5–10 mg of the epidermal layer was
minced and used for total RNA extraction with the TrizolH
reagent (Invitrogen, Carlsbad, CA, USA). The RNA pellet
was solubilized in 10 mL DEPC-treated distilled H2O.
Reverse transcription was performed with RNA samples
shown by UV spectrophotometry to be free of protein and
phenol. Briefly, 0.5 mg total RNA and 2 mL oligo dT 0.5 mg/
mL in DEPC-treated H2O qsp 14 mL were incubated at 65 C˚
for 5 minutes and immediately quenched on ice. After
adding 4 mL dithiothreitol 10 mM, 2 mL dNTP 10 mM and
8 mL First Strand buffer (Pharmacia, Uppsala, Sweden), the
solution was brought to 55 C˚ and completed with 200 U
Superscript IIH (Pharmacia). The solution was then incu-
bated at 55 C˚ for 60 minutes and at 85 C˚ for 15 minutes. The
cDNA obtained was stored at -80 C˚ until processing for
PCR.
Primers were designed with the aid of the software
PrimerExpress (Applied Biosystems Inc, Foster City, CA,
USA) for TNF-a (sense, CCG AGG CAG TCA GAT CAT
CTT; anti-sense, AGC TGC CCC TCA GCT TGA), IL-2
(sense, AAG AAT CCC AAA CTA ACC AGG AT; anti-
sense, TCT AGA CAT GAA GAT GTT TCA GTT CTC), IL-5
(sense, AAG AGA CCT TGG CAC TGC TTT C; anti-sense,
GGA ACA GGA ATC CTC AGA GTC TCA) and IFN-c
(sense, TGT AGC GGA TAA TGG AAC TCT TTT; anti-
sense, AAT TTG GCT CTG CAT TAT T). The predicted
sizes of the amplicons were 85 bp, 86 bp, 73 bp and 85 bp,
respectively. Real-time PCR was carried out with 15 ng
cDNA and 12.5 mL Sybr Green PCR Master Mix (Applied
Biosystems Inc) in an ABI 5700 Sequence Detection System
(Applied Biosystems Inc) with the following protocol:
2 minutes at 50 C˚, 10 minutes at 95 C˚ and 45 cycles of
15 seconds at 95 C˚ and 1 minute at 60 C˚. The primer
concentration was optimized as 200 nM for TNF-a and IFN-
c, 600 nM for IL-2 and 900 nM for IL-5. Amplification of the
reference gene b-actin (sense TAA TGT CAC GCA CGA
TTT CCC and anti-sense TCA CCG AGC GCG GCT at
300 nM) was performed for each sample. All PCRs were
carried out in duplicate for each sample. When differing
results were obtained the duplicate run was repeated. In
addition, each run contained duplicate wells with no cDNA
(non-template control) and wells with a pool of cDNA from
the 12 normal controls. The specificity of each primer was
verified both by assessing the band size on agarose gels and
by measuring the melting profile of the amplicon. All
reactions were subjected to dissociation curve analysis to
confirm that results were specific to one single amplified
product. The melting temperature for each of the amplicons
was 77 C˚ for IL-2, 79 C˚ for IL-5, 83 C˚ for TNF-a, 78 C˚ for
IFN-c and 84 C˚ for b-actin. The relative quantification of
cytokine transcripts was calculated according to Pfaffl’s
mathematical model:11
R~
E cytokineð ÞDCT cytokine gene control pool{sampleð Þ
E b{actinð ÞDCT b{actin gene control pool{sampleð Þ
where E is the efficiency of the amplification and CT is the
threshold cycle. The normal pool was arbitrarily ascribed an
R of 1. Samples with R.1 were considered overexpressed
and samples with R,1 were considered underexpressed for
the respective cytokine gene.
Association between qualitative parameters was analyzed
by x2 test and Fisher’s exact test, when appropriate.
Comparison of quantitative parameters between two groups
was performed by Student’s t test. Variance between two
groups was assessed by the Levene’s test. All analyses were
performed using the computer-based statistical software
package SPSS, version 13. An inference level of 0.05 was
established for all analysis.
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In general, demographic, clinical and laboratory features
of the studied subjects were equivalent among the groups;
however, patients with discoid lesion were slightly older
than subjects in the two other groups (Table 1). In addition,
patients with acute skin lesion had a higher Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) and higher
daily prednisone dose than those with discoid lesion. Four
of the 42 SLE skin biopsy samples were excluded because
there was no amplification signal for any of the tested
transcripts and thus these 4 samples were considered as
inappropriate RNA isolates (all were from non-affected
skin: 2 from patients with discoid lesion and 2 from patients
with acute lesion).
There was a wide variation in the expression level of the
four cytokines in the 38 valid samples (Figure 1). Among the
80 amplification reactions for the 4 cytokines in the 20
samples from patients with acute lesion (11 from affected
skin and 9 from non-affected skin), 12 (15%) showed
overexpression and 68 (85%) showed underexpression of
the respective cytokine. Among the 72 amplification reac-
tions in the 18 samples from patients with discoid lesion (10
from affected skin and 8 from non-affected skin), 9 (12.5%)
showed overexpression and 63 (87.5%) showed under-
expression of the respective cytokine. Despite the fact that
most of the 152 amplification reactions showed under-
expression, 18 (47%) of the 38 valid samples showed
overexpression of at least one cytokine and 3 (8%) showed
combined overexpression of two cytokines. A comparison of
the cytokine expression in affected (acute and discoid
lesion) and non-affected skin samples showed a trend
towards higher cytokine overexpression in affected skin
samples. Among the 84 amplification reactions in affected
skin samples (acute and discoid lesion), 16 (19%) showed
overexpression of the respective cytokine and among 68
amplification reactions in non-affected skin samples, only 5
(7%) showed overexpression of the respective cytokine
(p = 0.06). Overexpression of one and two cytokines was
observed in 10 (48%) and 3 (14%) of the 21 samples from
affected skin, respectively. In comparison, only 5 (29%)
samples from the 17 non-affected skin samples showed
overexpression of one cytokine and none had overexpres-
sion of two cytokines (p = 0.078).
The same trend was observed when analyzing patients
with discoid and acute lesions separately, although the
sample size was too small for statistical analysis. Among the
11 valid samples from affected skin with acute lesion, 2
(18.2%) had two cytokines overexpressed, 5 (45.5%) had one
cytokine overexpressed and 4 (36.4%) had all cytokines
underexpressed or undetectable. In contrast, among the 9
valid samples from unaffected skin of patients with acute
lesion, 3 (33%) had one cytokine overexpressed and 6 (67%)
had all cytokines underexpressed or undetectable. For
discoid lesions, among the 10 valid samples from affected
skin, 1 (10%) had two cytokines overexpressed, 5 (50%) had
one cytokine overexpressed and 4 (40%) had all cytokines
underexpressed or undetectable. In contrast, among 10
samples from unaffected skin of patients with discoid
lesion, 2 (20%) showed one cytokine overexpressed and 8
(80%) showed all cytokines underexpressed or undetectable.
Overexpression was observed for IL-5 in 8 samples
(5 affected and 3 non-affected skin), for IFN-c in 8 samples
(7 affected and 1 non-affected skin), for TNF-a in 3 samples
(all affected skin) and for IL-2 in 2 samples (1 affected and 1
non-affected skin). Among the 21 samples from affected
skin (acute and discoid lesion), two presented overexpres-
sion for IL-2, four for IL-5, three for TNF-a and seven for
INF- c. In contrast, among the 17 samples from non-affected
skin (from patients with acute and discoid lesion) one
showed overexpression for IL-2, three for IL-5, one for INF-c
and none for TNF-a.
All patients in this study were using prednisone in doses
varying from 5 to 20 mg/day, 18 (86%) of them were using
chloroquine diphosphate and none was receiving im-
munosuppressant therapy. The seven patients with no
overexpressed cytokine were using a prednisone dose of
15.71¡3.45 mg/day while the 14 patients with at least one
overexpressed cytokine had a mean prednisone dose of
12.68¡5.41 mg/day (p = 0.216). All three patients not receiv-
ing chloroquine diphosphate had at least one overexpressed
Table 1 - Demographic, clinical and laboratory characterization of the studied subjects.
Demographic, clinical and
laboratory features SLE with acute lesions (n = 11) SLE with discoid lesions (n = 10) Normal controls (n = 12) p Value
Age (years), mean¡SD 32.2¡9.2 44.0¡4.2 36.8¡7.97 0.003
Gender (female/male), n 9/1 9/1 11/1 0.628
Ethnic group (white/black), n 6/5 4/6 5/7 0.757
Disease duration (years), mean¡SD 10.7¡5.8 15.2¡7.8 – 0.181
Articular involvement 10 (91) 9 (90) – NS
Alopecia 5 (45) 6 (60) – NS
Mucosa ulceration 2 (18) 1 (10) – NS
Photosensitivity 11 (100) 10 (100) – NS
Cutaneous vasculitis 2 (18) 1 (10) – NS
Kidney involvement 6 (55) 4 (40) – NS
Hematologic involvement 3 (27) 2 (20) – NS
Serositis 1 (9) 1 (10) – NS
Neuropsychiatric involvement 2 (18) 0 (0) – NS
Antinuclear antibodies 10 (91) 9 (90) – NS
Hypocomplementemia 5 (45) 3 (30) – NS
SLEDAI, mean¡SD 16.8¡4.26 10.0¡3.71 – ,0.001
Prednisone dose (mg/day), mean¡SD 15.9¡4.36 11.25¡4.60 – 0.028
Antimalarial drugs 11 (100) 7 (70) – NS
Results are shown as number (%) unless stated otherwise.
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
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cytokine and one of them had two overexpressed cytokines.
Among valid samples from patients receiving chloroquine
diphosphate, 15 (40%) had at least one overexpressed
cytokine and only 2 (5%) had two overexpressed cytokines.
No association was observed between SLEDAI and cytokine
expression (data not shown). However, the 3 samples pre-
senting overexpression of more than one cytokine were deri-
ved from patients with intense and diffuse skin involvement.
DISCUSSION
This study has shown the considerable heterogeneity in
gene expression for IL-2, IFN-c, IL-5 and TNF-a in
keratinocytes from acute and discoid lesions from patients
with SLE. Although the majority of the amplification
reactions for mRNA extracted from patients with SLE
showed underexpression of the respective cytokine in
relation to the normal control pool, nearly half the SLE
specimens showed overexpression of at least one cytokine.
IFN-c and IL-5 were the most commonly overexpressed
cytokines. All patients receiving no drugs showed hyper-
expression of at least one cytokine but as their numbers
were few, the influence of medication on cytokine expres-
sion could not be clearly demonstrated. There was no
correlation between SLEDAI and cytokine expression but
there was a clear trend for cytokine overexpression in
samples from patients with extensive skin involvement.
Keratinocytes represent 95% of cells in the epidermis and
have been shown to be involved in the production of a
variety of cytokines, such as IL-1, TNF-a, IL-6 and granu-
locyte macrophage-colony-stimulating factor.12 Ultraviolet
radiation is thought to stimulate cytokine expression by
keratinocytes and this is probably relevant to the patho-
physiology of local and systemic inflammation in SLE.13-15
The observed low cytokine expression in epidermal kerati-
nocytes from patients with SLE as compared with the
normal keratinocyte pool in this study might be due to the
effect of medication and the small number of cells from
which mRNA was amplified. Indeed, the high Ct values
observed indicate the small amount of transcripts in the
original samples. However, the small amount of biological
material did not appear to be a limiting factor since the
reference gene b-actin mRNA was successfully amplified in
the 38 valid samples. In addition, all these samples were
normalized for 0.5 mg RNA to prepare the cDNA and there
was amplification of at least one cytokine mRNA in each
sample. In most of the samples in which cytokine over-
expression was present, only one of the four cytokine
genes was overexpressed and the others were either
underexpressed or not detected at all. Altogether these
Figure 1 - Distribution of the skin samples from patients with systemic lupus erythematosus (SLE) according to the expression of mRNA
for (A) interferon-c (IFN-c), (B) interleukin-5 (IL-5), (C) tumor necrosis factor-a (TNF-a) and (D) interleukin-2 (IL-2). Total RNA from the
keratinocyte layer of epidermis from acute lesions, discoid lesions and non-affected skin from patients with SLE was subjected to
reverse transcription and real-time PCR for the reference gene b-actin and the relevant cytokine genes. Cytokine transcript was
quantified relative to gene expression in polled samples from normal keratinocytes (R) and was classified into three groups:
not detected; underexpressed: R,1; & overexpressed: R.1.
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observations support the possibility that the low cytokine
expression profile observed was due to drug therapy and
not to the restricted amount of biological material from the
samples.
The skin layer used for mRNA extraction was obtained by
micro-dissection and was thus largely enriched for kerati-
nocytes. However, it is possible that minor amounts of
Langerhans cells and T lymphocytes were present in
various proportions in the samples. Since these cells are
known to secrete a rich panel of cytokines, this prospect
should be entertained as an additional possible explanation
for the variability in the cytokine profile among the SLE
samples.
Glucocorticosteroids can affect the expression of several
cytokines, including IL-2, IL-5, TNF-a and IFN-c.16-20 This
information is important for an appreciation of our results,
since all patients were receiving low to moderate doses of
prednisone. Brink et al. reported that even low doses of
steroids can inhibit cytokine synthesis in patients with
SLE.21 In another study, Swaak et al. observed that patients
with SLE taking prednisone at a dose of ,15 mg/day
showed a reduction in ‘‘ex-vivo’’ production of IL-6 and
TNF-a.22 Nu¨rnberg et al. have demonstrated that IL-6
protein expression in the epidermal basal layer is increased
in patients with SLE but this was not observed in those
patients using corticosteroids and antimalarial drugs.6 In
this study patients were continuously receiving prednisone
at a mean dose of 11.25 mg/day for those with discoid
lesion and 15.9 mg/day for those with acute lesions.
Furthermore, 18 patients were receiving chloroquine dipho-
sphate at a daily dose of 250 mg and 14 had used
thalidomide 200 mg/day on average 5 months before
entering the study.
The literature provides scarce information on the influ-
ence of treatment on cytokine mRNA expression in skin
lesions of patients with SLE. Increased expression of protein
and mRNA for IL-2, IFN-c and TNF-a, but not IL-1b and IL-
4, was observed in 8 skin samples from discoid lupus
patients by immunohistochemistry and semiquantitative
conventional PCR.8 Unfortunately, there is no information
on the use of medication in that study. Stein et al. studied
the presence of IL-2 and IL-5 mRNA by conventional RT-
PCR using whole skin from patients with different forms of
lupus skin lesions. IL-2 mRNA was not detected in 16 out of
the 19 skin samples while IL-5 was detected in all samples
from patients with SLE. Again no data are available about
treatment in those patients.7
In this study the IFN-c gene was overexpressed in 8 (19%)
of the samples, equally distributed between discoid and
acute lesions. Most of the samples with IFN-c overexpres-
sion were from involved skin (7 samples) against only one
from uninvolved skin. This observation suggests that
keratinocyte-derived IFN-c may play an active role in the
pathologic process of discoid and acute SLE skin lesions.
Although analyzing mRNA extracted from whole skin, the
findings of Stein et al7 are similar to ours in that IFN-c was
detected by conventional RT-PCR in 84% (16/19) of
miscellaneous lupus skin lesions. Similar results were
obtained by Toro et al.,8 who demonstrated increased
amounts of mRNA and protein for IL-2 and IFN-c in whole
skin from 8 patients with discoid lupus.
An interesting finding in this study was that the cytokine
expression profile was similar in discoid and acute lesions,
which suggests that keratinocyte-derived cytokines (IL-2,
IL-5, TNF-a and IFN-c) are important in the pathophysiol-
ogy of the disease but are not key factors in the differentia-
tion of the type of skin lesion in SLE. Although the cytokine
expression did not correlate with SLEDAI, it should be
pointed out that the three samples overexpressing more
than one cytokine were derived from patients with intense
and diffuse skin involvement. These three patients were
receiving treatment and it is possible that the therapeutic
regimen was insufficient to control the pathologic process,
allowing a full-blown expression of proinflammatory
cytokines and exuberant inflammation of the skin.
In conclusion, this study showed a heterogeneous cyto-
kine gene expression pattern in keratinocytes derived from
patients with SLE with discoid and acute skin lesions
receiving treatment with chloroquine diphosphate and low
dose prednisone. IFN-c and IL-5 were the most commonly
overexpressed cytokines, which suggests that both Th1 and
Th2 CD4+ cells may be involved in the pathophysiology of
SLE skin inflammation. IFN-c was the cytokine whose gene
expression was most closely associated with the presence of
clinical skin inflammation. Samples from patients with more
severe and extensive skin lesions presented higher fre-
quency of cytokine gene overexpression. The use of
prednisone and antimalarial drugs by most of the patients
may have contributed to the relatively low expression of
cytokines by epidermal keratinocytes in some of the
samples studied and this subject will be formally investi-
gated in appropriately designed trials.
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